Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.6%

104 terminated/withdrawn out of 824 trials

Success Rate

83.5%

-3.1% vs industry average

Late-Stage Pipeline

14%

116 trials in Phase 3/4

Results Transparency

60%

315 of 526 completed trials have results

Key Signals

77 recruiting315 with results76 terminated28 withdrawn

Enrollment Performance

Analytics

N/A

393(69.2%)

Phase 4

63(11.1%)

Phase 3

53(9.3%)

Phase 2

39(6.9%)

Phase 1

18(3.2%)

Early Phase 1

2(0.4%)

568Total

N/A(393)

Phase 4(63)

Phase 3(53)

Phase 2(39)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (824)

Showing 20 of 824 trials

NCT04798768Not ApplicableActive Not Recruiting

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Role: lead

NCT07262255Active Not Recruiting

WATCHMAN FLX Pro European Registry

Role: lead

NCT07669727Not Yet Recruiting

A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.

Role: lead

NCT05063565Phase 2Active Not Recruiting

TheraSphere With Durvalumab and Tremelimumab for HCC

Role: lead

NCT07254455Not ApplicableNot Yet Recruiting

CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)

Role: collaborator

NCT01117792Not ApplicableCompleted

Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation

Role: lead

NCT06959524Not ApplicableRecruiting

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

Role: lead

NCT06819865Recruiting

A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

Role: lead

NCT07106970Not ApplicableRecruiting

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)

Role: lead

NCT05303467Phase 1Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Role: lead

NCT07820930Not ApplicableNot Yet Recruiting

A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation

Role: lead

NCT06192758Not ApplicableActive Not Recruiting

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

Role: lead

NCT07377487Not ApplicableRecruiting

TheraSphere Japan Pre-Market Study

Role: lead

NCT07276815Not ApplicableRecruiting

OverStitch NXT Endoscopic Suture System

Role: lead

NCT07458217Not ApplicableNot Yet Recruiting

Combined CM and STN Stimulation for Motor Epilepsy